DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $822,700 | +19.4% | 3,316 | +15.5% | 0.19% | +29.7% |
| Q2 2023 | $689,280 | -8.7% | 2,872 | -4.1% | 0.14% | -14.2% |
| Q1 2023 | $755,112 | -15.5% | 2,996 | -11.0% | 0.17% | -22.1% |
| Q4 2022 | $893,669 | +1.8% | 3,367 | -1.0% | 0.22% | -8.8% |
| Q3 2022 | $878,000 | +9.8% | 3,401 | +7.8% | 0.24% | +9.2% |
| Q2 2022 | $800,000 | -31.4% | 3,156 | -20.6% | 0.22% | -21.9% |
| Q1 2022 | $1,166,000 | +5.3% | 3,976 | +18.1% | 0.28% | +1.5% |
| Q4 2021 | $1,107,000 | +310.0% | 3,366 | +168.2% | 0.28% | +41.0% |
| Q3 2021 | $270,000 | -70.2% | 1,255 | -62.9% | 0.20% | -24.4% |
| Q2 2021 | $907,000 | +138.7% | 3,381 | +100.1% | 0.26% | +79.2% |
| Q1 2021 | $380,000 | +36.2% | 1,690 | +34.7% | 0.14% | -15.8% |
| Q4 2020 | $279,000 | +3.3% | 1,255 | 0.0% | 0.17% | -12.3% |
| Q3 2020 | $270,000 | +46.7% | 1,255 | +20.7% | 0.20% | +29.1% |
| Q2 2020 | $184,000 | +58.6% | 1,040 | +23.8% | 0.15% | +28.0% |
| Q1 2020 | $116,000 | – | 840 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |